Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Life Technologies, Asuragen; Synthetic Genomics, Exxon Mobil; Immucor; Tecan; Millipore

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life Technologies today said that it and partner Asuragen have achieved CE marking and launched in Europe their BCR/ABL1 Quant Test, which is used to monitor treatment of chronic myeloid leukemia patients. Asuragen manufactures the test, and Life Technologies exclusively distributes the test, which runs on the Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument.


Synthetic Genomics and Exxon Mobil said this week that they have opened a new greenhouse facility at SGI's headquarters in La Jolla, Calif., as the partners aim to test whether large-scale quantities of affordable fuel can be produced from algae. The firms launched their biofuel collaboration a year ago.


Immucor has received a CE Mark for its Human Erythrocyte Antigen BeadChip for molecular immunohematology in vitro diagnostic purposes. The multiplex test performs extended typing of 32 red blood cell antigens simultaneously.


Tecan this week sold its sample management business to Nexus Biosystems for CHF 12 million ($11.5 million), with additional payments to Tecan of between $4.4 million and $7.7 million through 2012. Tecan said that the sale is part of its strategy to focus on its life sciences core business.


Millipore this week notified the US Securities and Exchange Commission that it plans to delist its stock from the New York Stock Exchange at the opening of the business on July 26 in connection to the completion of the sale of the company to Merck KGaA on July 14, which made Millipore a wholly owned subsidiary of Merck.